Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation, Fibrosis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | CCR2 Full-Length Membrane Lysate & Stable Cell Line. HEK293 Expressed (Native Glycosylation). Sequence Verified. Endotoxin <1EU/ug. | View CCR2 Products |
| Antigen (ECD) | CCR2 ECD-Fc Fusion Protein. Human/Mouse/Cyno orthologs. High purity (>95%), Endotoxin <1EU/μg. | View CCR2 Products |
| Gene Delivery | CCR2 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell line generation in calcium flux and chemotaxis assays. | View CCR2 Products |
| Ligand Control | CCL2 (MCP-1) Recombinant Protein. Natural ligand for binding competition and chemotaxis assays. | View CCL2 Products |
| Benchmark Ab | Anti-CCR2 (MLN1202 Biosimilar Sequence / Reference Sequence). Recombinant positive control. Endotoxin <1EU/ug. | View CCR2 Products |
| Validator | CCR2 siRNA Set. For knockdown verification and specificity control. | View CCR2 Products |
| Related Target A | CCL2 (MCP-1) – Primary natural ligand for chemotaxis and binding assays. | View CCL2 Products |
| Related Target B | CCR5 – Common dual-target partner and critical off-target liability for selectivity counter-screening. | View CCR5 Products |
| Related Target C | CSF1R – Complementary macrophage modulator for combination therapy development. | View CSF1R Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-Pass Transmembrane Structure (GPCR) | Lentiviral vectors optimized for native expression in stable cell lines, preserving 7-TM topology and native glycosylation. |
| Cross-species Cyno / Mouse Evaluation | Human / Cyno / Mouse CCR2 ortholog lentivirus or ECD-Fc proteins available. Sequence verified. |
| Receptor Subfamily Cross-reactivity (CCR1/CCR3/CCR5) | Homolog panel cell lines and proteins strictly verified by genomic PCR and sequence alignment for strict counter-screening. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (MLN1202 Biosimilar / Reference Sequence) provided for binding references and FACS. |
| False Positives in Signaling Assays | Validated siRNA set included to confirm target-specific downstream signaling; neutralizing ligand CCL2 also provided. |
Live CCR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The development of CCR2 (CD192) therapeutics is highly dynamic. First-generation small-molecule antagonists (e.g., PF-4136309, MLN1202) encountered efficacy hurdles and dose-limiting toxicities in broad immunology and atherosclerosis indications. The field has since pivoted toward fibrotic diseases (MASH/NASH, IPF), lupus nephritis, and tumor-associated macrophage (TAM) modulation. Modern pipelines increasingly evaluate CCR2 antagonism in combination with immune checkpoint inhibitors (PD-1/PD-L1) and CSF1R inhibitors. The shift in modality focus heavily leans towards small molecule allosteric inhibitors, monoclonal antibodies, bispecifics targeting the CCL2/CCR2 axis, and even CAR-macrophage approaches, driving the need for robust cell-based functional assays over simple soluble binding platforms. Next-generation R&D prioritizes CCR2/CCR5 dual-selectivity profiling, tissue-specific macrophage depletion, and isoform-specific biology (CCR2A vs CCR2B).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | AbbVie (Tobira), Takeda, BMS, Pfizer, Novartis | NASH / Fibrosis, Diabetic Nephropathy | Allosteric binding site validation; Calcium Flux / Chemotaxis (Need stable cell lines via Lentivirus) |
| Monoclonal Antibody | J&J, ChemoCentryx (Amgen), Eli Lilly, emerging biotechs | Solid Tumors / TME, Lupus, Immunology | Receptor Occupancy & Internalization assays; Cross-species binding (Human/Cyno/Mouse) |
| Bi-specific (CCL2-x) | Early-stage biotech | Oncology, Inflammation | Heterodimer validation; Ligand competition (Need CCL2 antigen) |
| CAR-T / CAR-Macrophage | Academic / Translational consortia | Solid Tumors, Fibrosis | Stable cell line construction (Need CCR2 Lentivirus) |